← All trials
NCT06089837
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 15, 2023
- Primary completion
- Feb 28, 2024
- Completion date
- Jun 30, 2024
- First posted
- Oct 18, 2023
- Last posted
- Oct 18, 2023
- Enrollment
- 16
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- EicOsis Human Health Inc.Lead sponsor
- EicOsis Human Health Inc.Study director
- New Zealand Clinical ResearchOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.